Sunday, January 03, 2016 12:33:33 PM
## source: finance.yahoo.com
Thu, 31 Dec 2015 18:01:00 GMT ~ SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of PharmaCyte Biotech, Inc. (OTCMKTS: PMCB)
answer;
the above is concerning.
must be why pps is dropping some.
[PR Newswire] - NEW YORK, Dec. 31, 2015 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of PharmaCyte Biotech Inc., ...
read full: http://finance.yahoo.com/news/shareholder-alert-bronstein-gewirtz-grossman-180100356.html
*********************************************************
Thu, 31 Dec 2015 14:24:46 GMT ~ PHARMACYTE BIOTECH, INC. Files SEC form 8-K, Non-Reliance on Previous Financials, Audits or Interim Review, Change in
read full: http://biz.yahoo.com/e/151231/pmcb8-k.html
*********************************************************
Wed, 30 Dec 2015 16:24:50 GMT ~ PharmaCyte Biotech End of Year Shareholder Update on Pancreatic Cancer and Diabetes Programs
[at noodls] - SILVER SPRING, Md., Dec. 30, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using ...
read full: http://www.noodls.com/view/75957AA68BB8F91D4D7D1CF9E20CAA6C66176461
*********************************************************
Wed, 30 Dec 2015 14:00:00 GMT ~ PharmaCyte Biotech End of Year Shareholder Update on Pancreatic Cancer and Diabetes Programs
[GlobeNewswire] - SILVER SPRING, Md., Dec. 30, 2015-- PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation ...
read full: http://finance.yahoo.com/news/pharmacyte-biotech-end-shareholder-pancreatic-140000367.html
*********************************************************
Thu, 17 Dec 2015 14:24:00 GMT ~ PharmaCyte’s Novel Diabetes Treatment Approach Could Prove Superior to Other Methods Under Development
[Accesswire] - BALTIMORE, MD / ACCESSWIRE / December 17, 2015 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new ...
read full: http://finance.yahoo.com/news/pharmacyte-novel-diabetes-treatment-approach-142400882.html
*********************************************************
$PMCB charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$PMCB company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/PMCB/company-info
Ticker: $PMCB
OTC Market Place: OTCQB
CIK code: 0001157075
Company name: PharmaCyte Biotech, Inc.
Company website: http://http://www.PharmaCyte.com
Incorporated In: NV, USA
Business Description: PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as \"Cell-in-a-Box\" This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer and its symptoms, and diabetes are being developed. PharmaCyte Biotech's treatment for solid tumor cancers involves encapsulating modified live cells capable of converting the prodrug ifosfamide into its active or \"cancer-killing\" form. These encapsulated live cells are placed as close to the tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. Ifosfamide is then given intravenously at one third the normal dose to eliminate adverse side effects. When the ifosfamide comes in contact with the encapsulated live cells through the circulatory system, the activation of the drug takes place at or near the tumor. This \"targeted chemotherapy\" has proven remarkably effective and safe to use in past clinical trials. PharmaCyte Biotech is also developing treatments for cancer based upon chemical constituents of the Cannabis plant. It is examining ways to exploit the benefits of Cell-in-a-Box technology in optimizing the anticancer effectiveness of Cannabis, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. In addition to developing treatments for pancreatic and other cancers, PharmaCyte Biotech is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte Biotech plans to encapsulate a human cell line which has been genetically engineered to produce, store and secrete insulin on demand at levels in proportion to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box technology.Less >>
$PMCB share structure
## source: http://www.otcmarkets.com
Market Value: $34,523,017 a/o Dec 31, 2015
Shares Outstanding: 750,826,823 a/o Dec 10, 2015
Float: 529,206,849 a/o Aug 26, 2014
Authorized Shares: 1,490,000,000 a/o Aug 26, 2014
Par Value: 0.0001
$PMCB extra dd links
Company name: PharmaCyte Biotech, Inc.
Company website: http://http://www.PharmaCyte.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=PMCB+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=PMCB+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=PMCB+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/news - http://finance.yahoo.com/q/h?s=PMCB+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/PMCB/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=PMCB+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/PMCB
DTCC (dtcc.com): http://search2.dtcc.com/?q=PharmaCyte+Biotech%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=PharmaCyte+Biotech%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=PharmaCyte+Biotech%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://http://www.PharmaCyte.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://http://www.PharmaCyte.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://http://www.PharmaCyte.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/PMCB
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001157075&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=PMCB&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=PMCB
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=PMCB+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=PMCB+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=PMCB
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=PMCB
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=PMCB+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/PMCB/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=PMCB+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/PMCB.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=PMCB
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (http://www.pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/PMCB
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/PMCB
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/PMCB:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=PMCB
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PMCB
$PMCB DD Notes ~ http://www.ddnotesmaker.com/PMCB
Recent PMCB News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 07/29/2024 08:05:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:59:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:58:35 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 08:05:04 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 05/30/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:40:20 PM
- PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease • Business Wire • 05/21/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 02:56:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 10:25:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/24/2023 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:02:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:01:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 10:00:10 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/22/2023 09:00:15 PM
- PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. • Business Wire • 11/15/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:25:09 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
- PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology • Business Wire • 10/31/2023 01:15:00 PM
FEATURED North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • Aug 5, 2024 9:00 AM
Fifty 1 Labs, Inc. and All-In-Extracts Announce Joint Venture to Develop and Release New Testosterone Boosting Supplement • BLEG • Aug 5, 2024 8:30 AM
Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM
POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • POET • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM